[ Contents | Search | Post | Reply | Next | Previous | Up ]
From: Holger Stenzel
Date: 10/10/03
Time: 6:17:02 AM
Remote Name: 217.228.127.247
Hello Larry, I do since nine months a treatment of the stuttering with Olanzapine. With a good result. The dose Olanzapine is 2,5 mg once at the evening. After some days an inner harmony which lasts about the process of the Medication quite continuously appeared. In parallel to that and furthermore it resulted in a clear easing of the strength of the stuttering. Oncoming blockades are to be overcome easier and there is a raised part of fluid periods. The result is an important improvement of the linguistic communication capability particularly in case of short dialogs and telephone calls. That increases to be able to overcome the confidence communicative tasks and decreases possibly the expectation attitude opposite the stuttering. The positive effects of Olanzapine do not lead to continuous symptom freedom. Short or also longer variations occur. You are not, however, as intense as without the medicine. The average improvement of the speaking-liquid under Olanzapine achieves the level of stuttering-strength decreased of natural periods. An almost fluid speech with slight blockades is frequent possible. I evaluate the improvement with at least 30 percent. Over the period of the Medikation there were not any important side effects up to now. The blood count shows normal values. Only the level Prolactin is minimal with 20 ug/l increases. There is an easy sleepiness sometimes in the day process. Over the period of the Medication my body mass reduced around 3 kg. I pay attention to healthy nutrition and am activates in the sport. I think no miracle drug is olanzapine. But a very interesting and hopeful beginning is. I inform Garald Maguire about my treatment. Olanzapine is an antagonist of serotonine and dopamine. The dopamine hypothesis of stuttering under consideration states that adults who stutter, as a group, have excessive dopamine in the striatal regions of the brain. The National Institute on Deafness and Other Communication Disorders (NIDCD) instructed a study for the Pre- and Post-Synaptic Dopamine Function in Developmental Stuttering: "Assessment of Pre- and Post-Synaptic Dopamine Function in Developmental Stuttering Using 11C-Raclopride and Positron Emission Tomography": http://clinicalstudies.info.nih.gov/detail/A_2002-DC-0008.html They know already results of this research? There will be a FDA - permission in next time? The best greetings from germany! Holger Stenzel